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Abstract
Background: Pain is an indication for total hip arthroplasty (THA) and it should be resolved post-surgery. Because
patients’ pain is typically treated pharmacologically we tested whether opioid use can be used as a surrogate for
patient-reported pain and as an indicator for early surgical failure. Specifically, we evaluated whether the amount
of opioids taken within the year after THA was associated with one and five years risk of revision surgery.
Methods: A cohort of 9943 THAs (01/2001-12/2012) was evaluated. Post-operative opioid use was the exposure of
interest and cumulative daily oral morphine equivalent (OME) amounts were calculated. Total OMEs/90-day periods
were categorised into quartiles. Revisions within one and five years were the outcomes of interest.
Results: Of the THAs, 2.0 % (N = 200) were revised within one year and 4.2 % (N = 413) within five years. After
adjustments for gender, age, surgical indication, co-morbidities, and other analgesics, revision was associated with
amount of OMEs in the second quarter after THA (days 91–180 after discharge). Patients on medium-high amounts of
OME (400-1119 mg) had higher risk of one (hazard ratio (HR) = 2.22, 95 % CI 1.08-4.56) and five year (HR = 1.66, 95 % CI
1.08-2.56) revision than a patient not taking opioids. During the same period, patients taking the highest amounts of
OMEs (≥1120 mg) had a 2.64 (95 % CI 1.03-6.74) times higher risk of one year and a 2.11 (95 % CI 1.13-3.96) times higher
risk of five year revision.
Conclusions: Opioid use 91–180 days post-surgery is associated with higher risk of revision surgery and therefore is an
early and useful indicator for surgical failure.
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Background
Pain is one of the main indications for total hip arthro-
plasty (THA) and presence of pain post-operatively is an
important indicator of procedure’s success [1, 2]. When
pain is still present post-operatively, and is not related to
another condition, it is typically the sign of a surgical com-
plication or a non-successful outcome. Post-operative
chronic pain has been estimated to occur in 7 % to 23 %
of THA patients [3]. Additionally, 4 % of primary THAs
are revised due to pain alone as post-operative pain is as-
sociated with revision THA [4, 5].
Typically, musculoskeletal pain is assessed using pa-
tient reported outcome tools [6]. While patient reported
outcomes tools can be useful in certain settings, the in-
struments used to measure patient reported outcomes
have varying validity and reliability, and can be challen-
ging to implement because of cost, and difficulty inte-
grating with workflows and gaining patient participation
[2, 7]. Opioids are recommended for moderate to severe
musculoskeletal pain after other pharmacological anal-
gesic interventions have failed, are contra-indicated, or
when refractory pain is present [8–10]. Because patients’
pain is usually treated pharmacologically, and opioids
are only recommended and should therefore only be
prescribed to a patient when enough pain is present, it is
possible this could be used as a surrogate for patient re-
ported pain assessment. Therefore, pharmaceutical data
offers a potentially efficient and economical approach
for assessing pain, which can be implemented as part of
the surveillance for large cohorts of patients for early
signals of potential surgical success.
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In order to determine whether pain medication use
could be used as an indicator for THA success, we
evaluated the prevalence of pain medication use in pa-
tients after THA surgery and its association with revi-
sion surgery. Specifically, we evaluated whether the
amount of opioids taken over the year after a primary
THA procedure was associated with the one year and
five years risk of revision after adjusting for other an-
algesic use, patient demographics, co-morbidities, and
indications for surgery.
Methods
Study design, setting, and sample
A retrospective cohort study of Australian patients
undergoing THA from 01/01/2001 to 31/12/2012 was
undertaken using data from the Department of
Veterans Affairs (DVA) administrative health claims
database. In the dataset, medications are coded ac-
cording to the World Health Organisation Anatomic,
Therapeutic and Chemical classification (ATC), and
the Australian Pharmaceutical Benefits Schedule (PBS)
item codes [11, 12]. Hospitalisations are coded ac-
cording to the International Classification of Diseases,
10th Revision, Australian Modification (ICD-10-AM)
[13] scheme.
The study sample included patients aged ≥18 years old
that underwent primary, elective, unilateral THA proce-
dures (identified using ICD-10-AM code 4931800).
Patients with multiple arthroplasties (inclusive of knee,
resurfacing procedures, or hip fractures) within 365 days
of the index THA were not included. Additionally, any
patients with history of malignancy or lymphoma (ICD-
10-AM C00.x–C26.x, C30.x–C34.x, C37.x–C41.x, C43.x,
C45.x–C58.x, C60.x–C76.x, C81.x–C85.x, C88.x,C90.x–
C97.x, C77.x–C80.x, C81.x–C85.x, C88.x, C96.x, C90.0,
C90.2) or dispensed antineoplastic and immunomodulat-
ing agents within their medication history (ATC codes
L01*) were not included. The obtained sample had
10,018 patients, of which 75 (0.7 %) were excluded as
they were considered outliers with their opioid use being
in the 99th percentile (i.e. > 7350 mg of oral morphine
equivalents (OME) in days 0–90, >9860 OME mg in
days 91–180, >11088 OME mg in days 181–270, and >
9840 OME mg in days 271–260) of the total use. The
final study sample had 9943 patients.
Outcomes of interest
The main outcome of interest was revision within one
year and five years. Using the hospitalisation dataset, the
following ICD-10-AM procedure codes were used to
identify revisions: 4932100, 4932400, 4932700, 4933000,
4933300, 4933900, 4934200, 4934500, and 4934600.
Exposure of interest
The cumulative daily amount, calculated as OME, of
oral and transdermal opioid medication (ATC code
N02A*), was calculated over the 360 days post discharge
from the THA procedure [14]. OMEs were calculated
using a standard conversion table to translate the dose
and type of each opioid a patient received into one mor-
phine equivalent dose [14] for overall comparison of an-
algesic dose. Total post-THA oral morphine equivalents
per 90 day exposure periods categorised into quartiles
were the exposure of interest of this study. If a patient
had a revision or died during the 360 day post-operative
period, the amount of opioid exposure was calculated
until the day before the event occurred. The cumulative
OME daily dose was calculated by summing the total
dose per day based on quantity of supply. The total
OME for a 90 day exposure time was the sum of all
OME daily doses for that period.
Covariates/confounders
Patient gender, age, primary diagnosis, co-morbidities, as
well as prior opioid use, and pre- and post-operative
non-steroidal anti-inflammatory drug (NSAID) use were
evaluated as possible confounders. Counts of comorbid-
ity were made using a modified RxRisk-V co-morbidity
measure, which identified 42 conditions [15]. In an at-
tempt to further control for the possibility of confounding
due to back pain (not specifically identified in the RxRisk-
V), we used a previously published Australian back pain
ICD-10-AM coding algorithm to identify patients with
history or concurrent condition of back pain (2 years prior
and post THA) [16, 17]. Pre-operative use of opioids was
identified using the same method as the post-operative
use (described in the exposure of interest section).
NSAIDs use was identified with ATC codes M01A* (anti-
inflammatory and antirheumatic products, non-steroids).
Statistical analysis
Descriptive statistics were used to describe the sample
and OME use per 90 day post-operative period. Cox-
proportional regression models were used to evaluate
the risk of one and five years revision and their associ-
ation with total OME amount per 90 day post-operative
period. Hazard ratios (HR), 95 % confidence intervals
(CI), and Wald Chi square P values are reported.
Because the amount of opioid intake naturally varies
during THA rehabilitation and in order to evaluate the
independent effect of the amount of opioid throughout
different periods of this rehabilitation, a model for each
specific post-operative 90 day exposure period was
created. In the first 90 days post-surgery (discharge days
1–90) the entire sample size was included in the model
(N = 9943), in the second 90 days (days 91–180) period
all survivors and non-revised cases from the first period
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were included (N = 9735), in the third 90 days (days
181–270) period all survivors and non-revised cases
from the second period were included (N = 9638), and
in fourth period (days 271–360) all survivors and
non-revised cases from the third period were included
(N = 9552). The categories of OME total amount
evaluated included no opioids (reference category),
low (less that the lowest quartile of the total dose in
that period), medium-low (between lowest quartile
and median dose), medium-high (between the median
dose and third quartile dose), and high (those taking
more than the highest quartile of opioids). All models
were adjusted for age (continuous), gender (male vs.
female), primary diagnosis for THA surgery (primary
coxarthrosis vs. other), co-morbidity disease count
(continuous), history of back pain (yes vs. no), prior
opioid total amount per 90 day period (continuous),
and NSAIDs use (yes vs. no). In the last time period
studied, the number of events was small (n = 24) and
therefore a multivariable model was not created. Pro-
portional hazard assumptions were met (checked
using time-dependent variables), collinearity was
checked using tolerance values (all values >0.10), and
outliers were reviewed and excluded from the sample.
The alpha level chosen for statistical significant was
0.05 and tests reported are two sided. SAS 9.4 (SAS
Institute, Cary, NC, USA) was used for all analyses.
Ethics
Ethics approval was obtained from the Australian
Department of Veterans’ Affairs (DVA, E010/010) and
the University of South Australia (P099-10) Human Re-
search Ethics Committees. A waiver of informed consent
was obtained for this study due to the nature of the data
used for this study.
Results
There were 9943 THAs evaluated, of which 2.0 % (N =
200) were revised within one year and 4.2 % (N = 413)
within five years of their index procedure. The cohort
was 50.8 % (N = 5046) female, the median age was
81.1 years old (interquartile range (IQR) = 76.6-84.6),
and 82.0 % (N = 8156) had a diagnosis of primary coxar-
throsis. The median number of co-morbidities patients
had was five (IQR 3–8) and the prevalence of back pain
was 14.4 % (N = 1430). See Table 1.
In patients who went on to be revised within one
year, there was a higher proportion of pre (range
24.0 %-47.0 %) and post-operative opioids users (range
34.5 %-45.5 %), than in those not revised (pre range
19.1 %-35.5 % and post range 18.5 %-37.3 %), Fig. 1.
Patients who went on to be revised within one year also
had higher use of post-operative NSAID in each quarter
after surgery (range 38.5 %-50.0 % compared to 29.7 %-
40.3 %). Before the THA, however, the proportion of
users taking NSAIDs was similar in both groups, Fig. 2.
Similar proportions of opioid use were observed for
cohorts of patients with five year estimates to one year
estimates (data not shown).
Revised patients used higher amounts of opioids (as
measured by medium-high and high OMEs in each spe-
cific exposure period) than those who were not revised.
See Fig. 3 for OMEs taken by the patients by 90 day pe-
riods (post THA) in patients who were revised within
one year and those who were not. The categorisation by
OME amounts and one and five year revision status are
specified in Table 2.
After adjustments we found that the amount of
OMEs used in the first 90 days after surgery was not
associated with a higher risk of revision within one or
five years. In the second 90 day period after THA (days
91 to 180), patients who had the medium-high amounts
of OME (OME between 400 and 1119 mg) had a 2.22
(95 % CI 1.08-4.56) times higher risk of one year revi-
sion and a 1.66 (95 % CI 1.08-2.56) times higher risk of
five year revision than a patient that was not taking any
opioids. During the same period, patients taking the
highest amounts of OMEs (OME ≥1120 mg) had a 2.64
Table 1 Total Hip Arthroplasty Sample Description, 2001-2012
Total Sample
N (%)
Total N All 9943 100.0
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1 and 2 690 6.9
3 and 4 1808 18.2
5 and 6 2518 25.3
≥7 3918 39.4
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IQR=Interquartile range. ICD - 10 - AM= International Classification of Diseases,
10th Revision, Australian Modification
Inacio et al. BMC Musculoskeletal Disorders  (2016) 17:122 Page 3 of 9
(95 % CI 1.03-6.74) times higher risk of one year revi-
sion and a 2.11 (95 % CI 1.13-3.96) times higher risk of
five year revision. In the third 90 days post-operative
period (days 181 to 270) there was not an association
between the levels of OMEs and revision. Finally, in
the last period evaluated (days 271–360) there was a
higher crude risk of one year revision in patients in
the medium-high and high levels of OME but we
could not adjust for other variables due to the small
number of events (n = 24). For the same time period,
there was not an adjusted higher risk of five years re-
vision. See Table 3.
Fig. 1 Proportion and 95 % Confidence Intervals of Patients Dispensed Opioids by 90 day Exposure Periods Pre- and Post-Total Hip Arthroplasty
by 1 Year Revision Status
Fig. 2 Proportion and 95 % Confidence Intervals of Patients Dispensed NSAIDs by 90 day Exposure Periods Pre- and Post-Total Hip Arthroplasty by 1
Year Revision Status
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Discussion
In this elderly cohort of THA patients, we estimated the
proportion of patients still taking pain relief at days 271
to 360 post-surgery to be between 19 % and 42 %, de-
pending on whether they went on to be revised or not.
These were the proportion of patients who were still tak-
ing some opioid medications during this period, a period
which is no longer considered surgical recovery. Our re-
sults are consistent with previous estimates that per-
sistent post-operative pain occurs in 7 % to 23 % of
primary THA patients [3]. When we investigated
opioid use, we found higher amounts of opioid medi-
cation taken after THA to be associated with higher
risk of revision. Specifically, patients taking 400 mg-
1120 mg and ≥1120 mg total amounts of OMEs during
days 91 to 180 post-operative, or 4-12 mg per day, had
a higher likelihood of revision surgery within one year
and five years.
Patient reported post-operative pain is an important
clinical THA outcome. In addition to its value in clinic-
ally assessing the procedure, it is also associated with
other hard endpoints, such as revision surgery [18].
Britton et al. reported that patients with severe or mod-
erate pain after surgery were more likely to have revi-
sions than patients with stiffness [18]. Of the patients in
their study with severe or moderate pain post-
operatively (n = 351 out of 2268), 28 % (n = 100) had a
revision within 2 years and 33 % (n = 115) within 5 years.
In our cohort, 42 % of patients who went on to be re-
vised were being treated for pain with opioids at one
year post-operatively, a similar number of patients com-
pared to Britton et al.’s study. In our study we also found
the amount of opioid use, and not just whether opioids
were being used, in the days 91–180, to be associated
with a higher risk of revision. The prevalence of opioid
use and amount of use also continued to be higher in
patients with revisions in the third and fourth quarter
post-operative suggesting a consistent trend but the ac-
tual risk of revision was not statistically significantly dif-
ferent, which could be due to the smaller number of
events in these models or possibly that the later use of
opioids is not as helpful as an indicator for revision.
Only one study, to our knowledge, reported both the
prevalence of pain (8.1 %) and opioid use (2.3 %) at two
years post-operatively. This study did not evaluate any
association of these indicators with revision surgery [19].
The prevalence of pain, measured either by the patient
reported instruments or opioid use, reported by Singh et
al.’s study is significantly lower than both Britton et al.’s
and our study. This is possibly due to the assessment be-
ing based on patients’ reported estimates rather than
pharmaceutical records, the former which could suffer
from response bias [19]. We are not aware of studies
that have included opioid use as a proxy for pain preva-
lence after joint arthroplasty and therefore no direct
comparison to our observations can be made. Addition-
ally, no comparisons to other literature can be made to
our observations of a higher risk of revision and total
amount of opioid use.
The use of opioid medication in our cohort was
significantly higher in the revision group before their
primary procedure. This observation agrees with reports
of other surgical procedures that the degree of pre-
operative pain is associated with post-operative pain
[20]. The use of opioids pre-operatively is associated
with poorer clinical outcomes in THA patients [21].
However, a higher utilisation of opioids before and after
surgery in patients who go on to require revision has
not been previously shown. It is worth noting that our
analyses were adjusted for other analgesic use as well in
Fig. 3 Proportion of Patients Taking Total Oral Morphine Equivalent Quartiles1 by 90-day Exposure Periods Post-Total Hip Arthroplasty and by 1
Year Revision Status. 1Quartiles amounts vary by 90 day period after surgery. See Table 2 for total amounts ranges per quartile per 90 day period
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an attempt to evaluate the independent effect of opioid
at each time period with the risk of revision (i.e. remove
any confounding introduced by other analgesic use).
Surrogate measures for the areas evaluated by pa-
tient reported outcome tools, such as analgesic uptake
for pain management, are viable alternatives to trad-
itional ascertainment of patient reported outcomes.
Prescription medication claims data are available in cer-
tain countries, and with proper understanding of the
limitations involved with these data, they are a possible
source for monitoring signals of potential poorer out-
comes [22–25]. In this study, we were able to obtain the
patients’ prescription dispensing and evaluate whether
the levels of opioid intake during the study period were
associated with the risk of revision surgery. Dispensing
of opioids seems to be a viable alternative for capturing
patient’s pain within 91–180 days post-operative and of-
fers an opportunity to identify patients at high risk of
revision surgery.
Our study has several limitations. The data used are
administrative and subjective to potential coding errors
and under-reporting. However, the limitations of our
data are not likely to be different between the groups
studied and we, therefore, expect this to have minimal




Revised within 1 Year Revised within 5 Years
No Yes No Yes
N (%) N (%) N (%) N (%)
Days 1 - 90
Total N 9743 98.0 200 2.0 9530 95.8 413 4.2
OME Quartiles No Opioid 6108 62.7 109 54.5 5986 62.8 231 55.9
Low (<150) 639 6.6 14 7.0 620 6.5 33 8.0
Medium-low (150–349.9) 1192 12.2 25 12.5 1167 12.3 50 12.1
Medium-high (350–839.9) 920 9.4 27 13.5 902 9.5 45 10.9
High (≥840) 884 9.1 25 12.5 855 9.0 54 13.1
Days 91-180a
Total N 9648 99.1 87 0.9 9435 96.9 300 3.1
OME Quartiles No Opioid 7793 80.8 57 65.5 7633 80.9 217 72.3
Low (<116.5) 453 4.7 3 3.5 438 4.6 18 6.0
Medium-low (116.5-399.9) 484 5.0 7 8.1 476 5.1 15 5.0
Medium-high (400–1119.9) 487 5.1 10 11.5 471 5.0 26 8.7
High (≥1120) 431 4.5 10 11.5 417 4.4 24 8.0
Days 181-270a
Total N 9586 99.5 52 0.5 9373 97.3 265 2.7
OME Quartiles No Opioid 7822 81.6 34 65.4 7654 81.7 202 76.2
Low (<116.5) 449 4.7 4 7.7 438 4.7 15 5.7
Medium-low (116.5-399.9) 442 4.6 6 11.5 432 4.6 16 6.0
Medium-high (400–1199.9) 450 4.7 4 7.7 438 4.7 16 6.0
High (≥1200) 423 4.4 4 7.7 411 4.4 16 6.0
Days 271-360a
Total N 9528 99.7 24 0.3 9315 97.5 237 2.5
OME Quartiles No Opioid 7767 81.5 14 58.3 7607 81.7 174 73.4
Low (<95) 456 4.8 1 4.2 444 4.8 13 5.5
Medium-low (95–399.9) 447 4.7 2 8.3 432 4.6 17 7.2
Medium-high (400–1216.7) 445 4.7 4 16.7 432 4.6 17 7.2
High (≥1216.8) 413 4.3 3 12.5 400 4.3 16 6.8
OME=oral morphine equivalents
aPatients with revisions or who died in the previous quarter were removed from denominator. In days 91–180 207 were removed (41 were revised and died, 94
died only, and 72 were revised only). In days 181–270 97 were removed (12 were revised and died, 62 died only, 23 were revised only). In days 271–360 86 were
removed (12 were revised and died, 58 died only, and 16 were revised only)
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impact on our estimations. The fact that medication can
be prescribed for many reasons and we do not know
whether the prescriptions obtained by our cohort were
for the joint studied is another limitations. Because of
this, we controlled our analysis for other reasons why
these patients may have received these medications. We
also restricted patients to include only those with one
joint procedure within one year. It is possible residual
confounding, due to other unknown or unavailable data,
is present. Our findings may also have limited generalis-
ability because we have an older cohort of patients. An-
other limitation includes our inability to account for
different opioid prescribing practices and preferences of
physicians and surgeons with the available data, which
could confound the reported findings. Further, there are
also few revisions occurring during days 180–360 and it
is possible that we were underpowered to estimate the
risk of one year revision for the number of opioid expo-
sures chosen for the study, however, the estimates were
similar to the 5 year risk estimates, which had models
with a substantial greater number of events. And while
we chose a method of opioid exposure classification that
accounted for both the time of exposure (i.e. each
90 day period) and the total amount of opioid use during
these times, we recognize that there are multiple ways to
evaluate opioid exposure, such as binary exposure to the
medication, average daily use, cumulative amount over
time, and this should be recognized when interpreting
our results and comparing to other studies on opioid
use in joint surgery. Our study is also an exploratory
analysis of the association of opioid amounts and the
risk of revision surgery in the short and mid-term, we
did not conduct multiple hypothesis adjustments to our
analysis but would recommend it for subsequent con-
firmatory analysis. Finally, while we used published
methodology to identify revision cases, it is possible
the revision surgery was linked to incorrect primary
procedures due to the lack of laterality in our data
[26, 27]. We do not believe this to be different be-
tween the groups studied and do not expect this to
impact our estimations.
Our study strengths include the captive DVA popula-
tion and comprehensive claims data available for these
patients’ services, which we used in this study to obtain
patients’ episodes of care as well as their prescription in-
formation. Additionally, there is no attrition, apart from
death, in this cohort, so all events are captured. Finally,
because of the type of data used to identify opioid use
our estimations do not suffer from patient response
bias- either from not filling out a questionnaire or not
Table 3 Crude and Adjusted Risk of 1 Year and 5 Year Revisions by Total Amount of Oral Morphine Equivalent (mg) Quartiles by 90
day Periods Post- Total Hip Arthroplasty
1 Year Revision 5 Years Revision
OMEs (mg range), Reference=No opioid Crude HR Adjusted HR P Value Crude HR Adjusted HR P Value
Days 1 - 90a Low (<150) 1.22 (0.70-2.12) 1.12 (0.64-1.96) 0.696 1.39 (0.96-2.00) 1.29 (0.89-1.86) 0.177
Medium-low (150–349.9) 1.16 (0.75-1.80) 1.01 (0.65-1.56) 0.973 1.16 (0.86-1.58) 1.06 (0.78-1.44) 0.715
Medium-high (350–839.9) 1.62 (1.07-2.47) 1.32 (0.86-2.04) 0.209 1.34 (0.97-1.85) 1.14 (0.82-1.59) 0.422
High (≥840) 1.56 (1.01-2.40) 1.02 (0.60-1.76) 0.943 1.69 (1.26-2.27) 1.24 (0.85-1.81) 0.269
Days 91 - 180a Low (<116.5) 0.91 (0.28-2.90) 0.77 (0.24-2.49) 0.667 1.48 (0.92-2.40) 1.35 (0.83-2.18) 0.230
Medium-low (116.5-399.9) 1.98 (0.90-4.34) 1.64 (0.74-3.66) 0.223 1.15 (0.68-1.94) 0.99 (0.58-1.69) 0.982
Medium-high (400–1119.9) 2.80 (1.43-5.49) 2.22 (1.08-4.56) 0.030 1.98 (1.32-2.97) 1.66 (1.08-2.56) 0.022
High (≥1120) 3.14 (1.60-6.15) 2.64 (1.03-6.74) 0.042 2.15 (1.41-3.27) 2.11 (1.13-3.96) 0.020
Days 181 - 270b Low (<116.5) 2.05 (0.73-5.77) 1.70 (0.60-4.84) 0.321 1.34 (0.80-2.27) 1.21 (0.72-2.06) 0.472
Medium-low (116.5-399.9) 3.11 (1.31-7.41) 2.42 (1.00-5.87) 0.050 1.48 (0.89-2.46) 1.25 (0.75-2.10) 0.396
Medium-high (400–1199.9) 2.05 (0.73-5.78) 1.28 (0.43-3.85) 0.659 1.44 (0.87-2.39) 1.01 (0.59-1.73) 0.977
High (≥1200) 2.16 (0.77-6.10) 0.48 (0.08-3.01) 0.432 1.60 (0.96-2.67) 0.65 (0.27-1.60) 0.349
Days 271 - 360c Low (<95) 1.22 (0.16-9.31) NA NA 1.35 (0.77-2.36) 1.19 (0.67-2.10) 0.238
Medium-low (95–399.9) 2.47 (0.56-10.88) NA NA 1.79 (1.09-2.95) 1.55 (0.94-2.58) 0.088
Medium-high (400–1216.7) 4.96 (1.63-15.07) NA NA 1.81 (1.10-2.97) 1.41 (0.83-2.38) 0.203
High (≥1216.8) 4.01 (1.15-13.96) NA NA 1.93 (1.16-3.23) 1.22 (0.55-2.73) 0.627
OME=oral morphine equivalents. NA= Not applicable
aModels adjusted for age, gender, primary diagnosis, RxRisk-V number of co-morbidities, back pain, prior opioid use, and NSAID use
b1 year revision model adjusted for prior opioid use, back pain and RxRisk. 5 year revision model adjusted for age, gender, primary diagnosis, RxRisk-V number of
co-morbidities, back pain, prior opioid use, and NSAID use
c1 year revision estimates could not be adjusted because of the small number of events in this period (N=24). 5 year revision model adjusted for age, gender,
primary diagnosis, RxRisk-V number of co-morbidities, back pain, prior opioid use, and NSAID use
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filling it out properly due to lack of understanding of
questions [28].
Conclusion
In this cohort of older THA patients, opioid medication
in the year prior to and after surgery was 19 % to 42 %
and varied between patients who had a revision surgery
or not. Patients using moderate to high amounts of opi-
oid, during days 91–180 post surgery had a higher risk
of revision within one and five years than patients not
taking opioids. The observation that patients with revi-
sion procedures always had higher opioid consumption
than patients that did not go on to be revised, including
in the pre-operative period, offers a window of oppor-
tunity for surgeons to address opioid use and its possible
post-operative impact pre surgery, when more frequent
contact and surgical counselling is occurring. Addition-
ally, identifying that higher amounts of opioids post-
surgery indicate a higher risk of revision suggests that
opioid use, specifically within 91–180 days, is a proxy
for pain and a useful indicator for revision and should
be closely monitored by healthcare providers.
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